ACAT2 and melanoma: By this approach, we found that ACAT2, the first enzyme in the cholesterol synthesis pathway, and SOAT, the enzyme acting in the intracellular esterification of cholesterol and the formation of cholesteryl esters, play a role in drug resistance and can be proposed as targets for modulation of BRAFi response in melanoma.